Kymera Therapeutics, Inc. (KYMR) stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.
For the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration revenue for the quarter came in at $7.4 million, a substantial decrease from $47.9 million in the prior-year quarter. Both figures missed consensus analyst estimates.
The company highlighted its strong cash position of $851 million as of December 31, which is expected to fund operations into mid-2027. However, investors appeared to focus on the disappointing quarterly performance, driving the stock down in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.